Clinical Trial Update: Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on KPI-121 for dry eye disease shows safety and efficacy data in subjects with Keratoconjunctivitis Sicca/Dry Eye Syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Keratoconjunctivitis Sicca

Drugs mentioned

• KPI-121

Snippet

Sponsor: Kala Pharmaceuticals, Inc. | Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Status: COMPLETED | Results posted: 2021-01-06